VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ The subject's parent/legal guardian must be        │ The subject's parent/legal guardian must be        │     100 │
│ willing to give permission for the subject to      │ willing to give permission for the subject to      │         │
│ participate in the trial, and provide written      │ participate in the trial, and provide written      │         │
│ informed consent for the subject. In addition,     │ informed consent for the subject. In addition,     │         │
│ assent must be obtained from paediatric subjects   │ assent must be obtained from paediatric subjects   │         │
│ who possess the intellectual and emotional ability │ who possess the intellectual and emotional ability │         │
│ to comprehend the concepts involved in the trial.  │ to comprehend the concepts involved in the trial.  │         │
│ If the paediatric subject is not able to provide   │ If the paediatric subject is not able to provide   │         │
│ assent (due to age, maturity and/or inability to   │ assent (due to age, maturity and/or inability to   │         │
│ intellectually and/or emotionally comprehend the   │ intellectually and/or emotionally comprehend the   │         │
│ trial), the parent/legal guardian's written        │ trial), the parent/legal guardian's written        │         │
│ Informed Consent for the subject will be           │ Informed Consent for the subject will be           │         │
│ acceptable for the subject to be included in the   │ acceptable for the subject to be included in the   │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of an appropriate mild or moderate        │ Presence of an appropriate mild or moderate        │     100 │
│ bleeding soft tissue or hepatic parenchyma Target  │ bleeding soft tissue or hepatic parenchyma Target  │         │
│ Bleeding Site (TBS) identified intra-operatively   │ Bleeding Site (TBS) identified intra-operatively   │         │
│ by the surgeon                                     │ by the surgeon                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to firmly press trial treatment at TBS     │ Ability to firmly press trial treatment at TBS     │     100 │
│ until 4 minutes after randomisation                │ until 4 minutes after randomisation                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with known intolerance to blood products  │ Subjects with known intolerance to blood products  │     100 │
│ or to one of the components of the study product   │ or to one of the components of the study product   │         │
│ or is unwilling to receive blood products          │ or is unwilling to receive blood products          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects, who are of childbearing age (i.e. │ Female subjects, who are of childbearing age (i.e. │     100 │
│ adolescent), who are pregnant or nursing           │ adolescent), who are pregnant or nursing           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject is currently participating or plans to     │ Subject is currently participating or plans to     │     100 │
│ participate in any other investigational device or │ participate in any other investigational device or │         │
│ drug without prior approval from the Sponsor       │ drug without prior approval from the Sponsor       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who are known, current alcohol and/or     │ Subjects who are known, current alcohol and/or     │     100 │
│ drug abusers                                       │ drug abusers                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects admitted for trauma surgery               │ Subjects admitted for trauma surgery               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with any pre or intra-operative findings  │ Subjects with any pre or intra-operative findings  │     100 │
│ identified by the surgeon that may preclude        │ identified by the surgeon that may preclude        │         │
│ conduct of the study procedure                     │ conduct of the study procedure                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject with TBS in an actively infected field     │ Subject with TBS in an actively infected field     │     100 │
│ (Class III Contaminated or Class IV Dirty or       │ (Class III Contaminated or Class IV Dirty or       │         │
│ Infected)                                          │ Infected)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ TBS is from large defects in arteries or veins     │ TBS is from large defects in arteries or veins     │     100 │
│ where the injured vascular wall requires repair    │ where the injured vascular wall requires repair    │         │
│ with maintenance of vessel patency and which would │ with maintenance of vessel patency and which would │         │
│ result in persistent exposure of the EVARREST™ or  │ result in persistent exposure of the EVARREST™ or  │         │
│ SURGICEL® to blood flow and pressure during        │ SURGICEL® to blood flow and pressure during        │         │
│ healing and absorption of the product              │ healing and absorption of the product              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ TBS with major arterial bleeding requiring suture  │ TBS with major arterial bleeding requiring suture  │     100 │
│ or mechanical ligation                             │ or mechanical ligation                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bleeding site is in, around, or in proximity to    │ Bleeding site is in, around, or in proximity to    │     100 │
│ foramina in bone, or areas of bony confine         │ foramina in bone, or areas of bony confine         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Paediatric subjects aged ≥28 days (≥ 1 month) to   │ Paediatric subjects aged =28 days (= 1 month) to   │      98 │
│ \<18 years, requiring non-emergent open hepatic,   │ <18 years, requiring non-emergent open hepatic,    │         │
│ abdominal, retroperitoneal, pelvic or thoracic     │ abdominal, retroperitoneal, pelvic or thoracic     │         │
│ (non-cardiac) surgical procedures. i) The first 36 │ (non-cardiac) surgical procedures. i) The first 36 │         │
│ subjects to be enrolled will be subjects aged ≥1   │ subjects to be enrolled will be subjects aged =1   │         │
│ years to \<18 years. ii) The next 4 subjects to be │ years to <18 years. ii) The next 4 subjects to be  │         │
│ enrolled will be subjects aged ≥28 days to \<1     │ enrolled will be subjects aged =28 days to <1 year │         │
│ year                                               │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 28 Days  │ Subjects who are known, current alcohol and/or │      37 │
│                                   │ drug abusers                                   │         │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 17 Years │ Subjects admitted for trauma surgery           │      38 │
╘═══════════════════════════════════╧════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 92.0625
OverAll Ratio: 95.03125
